These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17122935)

  • 1. Liver transplantation in transthyretin amyloidoses. When the neurological benefit outweighs the risk.
    Mascalchi M; Salvi F
    Neurol Sci; 2006 Nov; 27(5):297-8. PubMed ID: 17122935
    [No Abstract]   [Full Text] [Related]  

  • 2. Familial amyloid polyneuropathy and liver transplantation.
    Monteiro E; Freire A; Barroso E
    J Hepatol; 2004 Aug; 41(2):188-94. PubMed ID: 15288465
    [No Abstract]   [Full Text] [Related]  

  • 3. Poor outcome after liver transplantation for transthyretin amyloid neuropathy in a family with an Ala36Pro transthyretin mutation: case report.
    Muller KR; Padbury R; Jeffrey GP; Poplawski NK; Thompson P; Tonkin A; Harley HA
    Liver Transpl; 2010 Apr; 16(4):470-3. PubMed ID: 20373457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of liver transplantation for familial amyloidotic polyneuropathy.
    Sharma P; Perri RE; Sirven JE; Zeldenrust SR; Brandhagen DJ; Rosen CB; Douglas DD; Mulligan DC; Rakela J; Wiesner RH; Balan V
    Liver Transpl; 2003 Dec; 9(12):1273-80. PubMed ID: 14625827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy: lessons learned from liver transplantation for transthyretin-amyloidosis.
    Suhr OB; Holmgren G; Lundgren E
    Liver Transpl; 2004 Dec; 10(12):1551-3. PubMed ID: 15558840
    [No Abstract]   [Full Text] [Related]  

  • 6. Amyloid turnover after liver transplantation in FAP.
    Obayashi K; Ueda M; Jono H; Yamashita T; Yazaki M; Kametani F; Ohya Y; Inomata Y; Ikeda S; Ando Y
    Amyloid; 2011 Jun; 18 Suppl 1():187-9. PubMed ID: 21838482
    [No Abstract]   [Full Text] [Related]  

  • 7. Combined liver-kidney transplantation in familial amyloidotic polyneuropathy TTR V30M: nephrological assessment.
    Lobato L; Beirão I; Seca R; Pessegueiro H; Rocha MJ; Queiroz J; Gomes M; Henriques AC; Teixeira M; Almeida R
    Amyloid; 2011 Jun; 18 Suppl 1():190-2. PubMed ID: 21838483
    [No Abstract]   [Full Text] [Related]  

  • 8. Rapidly Progressive Transthyretin-Mediated Amyloidosis in a Domino Liver Transplant Recipient of a Ser23Asn Donor.
    Dixit N; Castano A; Farr MJ; Traub R; Lentzsch S; Brown RS; Maurer MS; Brannagan TH
    J Clin Neuromuscul Dis; 2016 Mar; 17(3):142-5. PubMed ID: 26905915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe congestive heart failure with cardiac liver cirrhosis 10 years after orthotopic liver transplantation for familial amyloidotic polyneuropathy.
    Sakashita N; Ando Y; Haraoka K; Terazaki H; Yamashita T; Nakamura M; Takeya M
    Pathol Int; 2006 Jul; 56(7):408-12. PubMed ID: 16792551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transthyretin-related familial amyloidotic polyneuropathy.
    Ando Y; Nakamura M; Araki S
    Arch Neurol; 2005 Jul; 62(7):1057-62. PubMed ID: 16009758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitreous amyloidosis in two sisters as the indication of transthyretin-related familial form of systemic amyloidosis among liver transplantation candidates.
    Niemczyk R; Brydak-Godowska J; Kecik D; Wagner T; Lewandowski P; Kecik M; Zygier D; Ołdakowska-Jedynak U
    Transplant Proc; 2009 Oct; 41(8):3085-7. PubMed ID: 19857683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A homozygote case of familial amyloid polyneuropathy amyloidgenic transthyretin Val30Met in a non-endemic area.
    Kumabe Y; Miura A; Yamashita T; Oshima T; Misumi Y; Ueda M; Obayashi K; Horibata Y; Jono H; Ando Y; Uchino M
    Amyloid; 2011 Jun; 18 Suppl 1():169-70. PubMed ID: 21838475
    [No Abstract]   [Full Text] [Related]  

  • 13. Domino liver transplantation: risks and benefits.
    Ericzon BG; Larsson M; Wilczek HE
    Transplant Proc; 2008 May; 40(4):1130-1. PubMed ID: 18555132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inability of mutant transthyretin V30M to cross the blood-eye barrier.
    Beirão JM; Moreira LV; Lacerda PC; Vitorino RP; Beirão IB; Torres PA; Costa PP
    Transplantation; 2012 Oct; 94(8):e54-6. PubMed ID: 23080516
    [No Abstract]   [Full Text] [Related]  

  • 15. [Immunological and serological laboratory tests: transthyretin].
    Ando Y
    Rinsho Byori; 2005 Jun; 53(6):554-7. PubMed ID: 16026084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Amyloid polyneuropathies--biochemical and genetic aspects].
    Delpech M; Valleix S
    Bull Acad Natl Med; 2012 Oct; 196(7):1309-18; discussion 1318-20. PubMed ID: 23815016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of liver transplantation and tafamidis in hereditary transthyretin amyloidosis caused by transthyretin Leu55Pro mutation: a case report.
    Kon T; Misumi Y; Nishijima H; Honda M; Suzuki C; Baba M; Inomata Y; Obayashi K; Ando Y; Tomiyama M
    Amyloid; 2015; 22(3):203-4. PubMed ID: 26123280
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of aging on the progression of neuropathy after liver transplantation in transthyretin Val30Met amyloidosis.
    Koike H; Hashimoto R; Tomita M; Kawagashira Y; Iijima M; Nakamura T; Watanabe H; Kamei H; Kiuchi T; Sobue G
    Muscle Nerve; 2012 Dec; 46(6):964-70. PubMed ID: 23225390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presence of autoantibody against ATTR Val30 Met after sequential liver transplantation.
    Suhr OB; Lundgren E
    Transplantation; 2002 Mar; 73(5):674-5. PubMed ID: 11907408
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of late amyloid cardiomyopathy following liver transplantation for hereditary Val30Met transthyretin amyloidosis.
    Gondi KT; Nazir S; Grande R; Hummel SL
    Amyloid; 2021 Sep; 28(3):215-216. PubMed ID: 33818235
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.